IP Library Granted Patent US 10,450,596
Granted Patent B2
US 10,450,596 · App. 15/129,167 · Granted Oct 22, 2019

L-2-hydroxyglutarate and stress induced metabolism

Inventors: Andrew M. Intlekofer (New York, NY); Craig B. Thompson (New York, NY)
Assignee: Memorial Sloan-Kettering Cancer Center
C12Q1/32A61K31/711G01N33/5091G01N2500/10G01N2800/7038
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,450,596
App. No.
15/129,167
Granted
Oct 22, 2019
Kind
B2
Abstract

The present disclosure provides, among other things, methods and compositions for diagnosing and treating stress-induced injuries, hypoxia in particular. The present invention is based, in part, on the novel discovery that a metabolite, L-2-hydroxyglutarate, and certain enzymes and substrates regulating its metabolism, mediate stress-induced cellular mechanisms. In some embodiments, provided methods and compositions are used to diagnose and treat diseases with hypoxia-induced injuries. In some embodiments, provided methods and compositions are used to modulate cell pluripotency or differentiation in vivo or in vitro.

Claims (11)

1. A method for increasing activity of L-2-hydroxyglutarate dehydrogenase in a cancer cell comprising steps of:

contacting the cancer cell with a vector comprising a nucleic acid molecule encoding L-2-hydroxyglutarate dehydrogenase such that L-2-hydroxyglutarate dehydrogenase expression is elevated.

2. The method of claim 1 , wherein the cell is contacted with a sufficient amount of the vector encoding L-2-hydroxyglutarate dehydrogenase to promote differentiation.

3. The method of claim 1 , wherein the cell is in a subject suffering from cancer, wherein contacting the cell comprises administering to the subject the vector encoding L-2-hydroxyglutarate dehydrogenase.

4. The method of claim 3 , wherein the subject has wild type isocitrate dehydrogenase 1 or 2 (IDH1/2).

5. The method of claim 1 , wherein the cell is contacted with an amount of the vector expressing L-2-hydroxyglutarate dehydrogenase sufficient to inhibit histone methylation.

6. The method of claim 1 , wherein the cell is a tumor cell and the amount of the vector encoding L-2-hydroxyglutarate dehydrogenase is therapeutically effective to inhibit tumor angiogenesis.

7. The method of claim 5 , wherein the inhibited histone methylation is H3K9me3.

8. The method of claim 1 , wherein the expression level is elevated compared to an empty vector control.

9. The method of claim 1 , wherein the cancer cell is a glioblastoma cancer cell.

10. The method of claim 1 , wherein the expression level is elevated to a level above endogenous levels of a non-cancer cell.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jan 4, 2017
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041239/0506 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: INTLEKOFER, ANDREW M.; THOMPSON, CRAIG B.
To: MEMORIAL SLOAN-KETTERING CANCER CENTER
Reel/Frame 039895/0876 →
Continuity (2)
Provisional Application 61972091 · Mar 28, 2014
Related Publication 20170175164A1 · Jun 22, 2017